Rimonabant/168273-06-1 Weight loss, Obesity, Appetite control

Rimonabant is a selective cannabinoid receptor-1 (CB1) blocker. It was primarily developed to manage severe obesity and metabolic risk factors by suppressing appetite and reducing cravings through the central nervous system. Additionally, clinical data demonstrated its efficacy in improving lipid profiles and enhancing glycemic control, independent of weight loss. Beyond metabolic management, its mechanism of action showed significant promise in smoking cessation therapy by disrupting the brain’s reward pathways associated with nicotine dependence.